Stat5b transgenic lymphoma mouse model and therapeutic strategies

Description:

Current State of the Art:

Based on the age of the patient and the stage of lymphoma different regimens of radiation and chemotherapy are employed. In regard to drugs, most patients with early stage lymphoma are treated with a cocktail called "ABVD" chemotherapy, which contains the drugs Adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine. Later stage lymphoma may be treated with high levels of ABVD or different drugs with more aggressive regimens.

Problems with the Current Art:

Both the lymphoma and treatments suppress the patient's immune system, increasing the risk for infections. Also, treatments can negatively affect fertility.

Advantages of the Current Invention:

The current invention describes the use of naturally occurring compounds from the anticancer group consisting of xanthohumal, apigenin, and combinations thereof at a targeted pathway level. Lymphomagenesis can be reduced, inhibited, or prevented by inhibiting STAT5b activation, down regulating expression of CD 150, or both in immune cells in an animal model that spontaneously develops lymphomas. This method of treatment holds promise of eliminating side effects experienced with current drugs.

Case ID: GRU #2012-011

 

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Carl Clark
Director Technology Transfer
Augusta University
caclark@augusta.edu
Inventors:
Jin-Xiong She
Bo Chen
Keywords:
© 2017. All Rights Reserved. Powered by Inteum